TAVR in Patients with Moderate Aortic Stenosis with At-Risk Features

Authors, Journal, Affiliations, Type, DOI

Overview

PROGRESS randomized 744 patients aged 65 years or older with moderate aortic stenosis and at least one at-risk feature to transfemoral TAVR with a balloon-expandable SAPIEN 3 platform or guideline-recommended clinical surveillance. At two years the composite of death from any cause or a heart-failure event occurred in 16.7% with TAVR and 23.9% with surveillance (risk difference −7.2 percentage points; hazard ratio 0.67, 95% CI 0.48–0.93; P=0.02). The benefit was driven by heart-failure events and hospitalization, not by mortality, which was 8.4% versus 7.3%. The trial therefore converts a heterogeneous "moderate" label into an actionable phenotype defined by at-risk features, and does so despite 57.4% of the surveillance arm undergoing aortic-valve replacement within two years.

Keywords

Moderate aortic stenosis, transcatheter aortic-valve replacement, clinical surveillance, at-risk features, heart-failure hospitalization, aortic-valve calcium score, left ventricular ejection fraction, diastolic dysfunction, randomized controlled trial

Key Takeaways

Background and Rationale

Methods

Patients

Primary Endpoints

Secondary and Additional Outcomes

Progression in the Surveillance Arm

Procedural Outcomes

Interpretation

Limitations of the Document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated